人工抗體治療癌症

技術進步和層級製藥公司日益成長的興趣推動了工程抗體的成長

這項研究分析了癌症工程抗體療法的出現，並檢驗了推動其採用的因素。單株抗體的限制正在推動對新形式的需求。該公司正在開發多特異性抗體，例如雙特異性和三特異性抗體，以及抗體片段，例如 Fab 和 VHH。這些工程抗體旨在同時結合多個靶點，從而提高療效並克服腫瘤抗藥性。創新的工程技術使研究人員能夠實現更好的 PK/PD，包括延長半衰期和降低免疫抗原性。對工程抗體的需求也促使層級製藥公司透過與領先的開發商合作並將多特異性抗體添加到其產品組合中來擴展其治療專業知識。開發人員還與基於人工智慧/機器學習的技術提供者合作，以增強他們的抗體產品。

這項研究確定了不同的抗體形式並檢驗了它們在疾病領域的適用性。為了促進工程抗體形式的創建，我們重點介紹開發創新抗體發現、工程和開發服務的關鍵參與者。我們研究了驅動和抑制癌症工程抗體療法成長的因素，並確定市場參與企業和相關人員應該利用的領域變化所帶來的成長機會。

目錄

策略要務

• 為什麼成長如此困難？
• The Strategic Imperative 8（TM）
• 關鍵策略要務對癌症人工抗體療法的影響
• 成長機會推動Growth Pipeline Engine（TM）
• 調查方法

成長機會分析

• 分析範圍
• 分割

成長發電機

• 生長促進因子
• 成長抑制因素
• 需要人工抗體
• 目前抗體療法的挑戰
• 工程抗體療法如何克服傳統抗體的挑戰

人工抗體療法的演變

• 人工抗體形式 - 多特異性以獲得更好的功效
• 研究癌症的 ADC
• 抗體片段/構建模組
• 分析不同抗體形式的不同構建模組
• 主要創新者
• 人工抗體開發的優先領域
• 抗體工程 - 開發更好抗體的策略
• BsAb 格式類型
• 多特異性抗體形式/工程技術
• 多特異性抗體在疾病領域的應用
• 癌症人工抗體的新興創新
• BsAb 的免疫標靶策略
• Fab 的治療效用
• 二價抗體片段F(ab')2的治療效用
• scFv 的治療效用
• 奈米抗體/VHH 的治療效用
• 三特異性抗體的治療效用
• 四特異性抗體的治療效用
• 層級癌症製藥公司的興趣日益濃厚

抗體發現和開發

• 抗體開發平台-人源化小鼠
• 抗體開發平台-基因改造動物
• 實現高通量篩檢的策略
• 微流體和基於液滴的技術的創新
• 單細胞分析的創新
• 功能篩檢的創新
• 在抗體開發的各個方面利用 AI/ML

相關人員

• 最近用於抗體治療開發的私人資金籌措

充滿成長機會的世界

• 成長機會 1：改進最佳化
• 成長機會2：專注於新的抗體形式
• 成長機會 3：應用擴展

附錄

• 技術成熟度等級 (TRL)：解釋

下一步

Technology advances and increasing interest from Tier I pharmaceuticals are driving the growth of engineered antibodies

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and VHH. These engineered antibodies are created to have heightened efficacy and overcome tumor resistance by binding to multiple targets simultaneously. Innovative engineering technologies are helping researchers achieve better PK/PD with an enhanced half-life and less immunogenicity. The demand for engineered antibodies is also driving Tier I pharmaceuticals to collaborate with key developers to expand their therapeutic expertise by adding multispecific antibodies to their portfolios. Developers, on their part, are partnering with AI/ML-based technology providers to enhance their antibody offerings.

The study identifies the different antibody formats and examines their applicability across disease areas. It looks at the key players developing innovative antibody discovery, engineering, and development services to facilitate the creation of engineered antibody formats. The study examines the factors driving and restraining the growth of engineered antibody therapeutics for cancer and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key Questions This Study Answers

1. What are the key drivers and restraints in the development of engineered antibodies?

2. What are the applications of engineered antibodies across different disease areas? What are the key focus areas of R&D efforts?

3. Which disease areas are seeing increased adoption?

4. What are the key innovative discoveries and engineering technologies?

5. What does the funding landscape look like?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Engineered Antibody Therapeutics for Cancer
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation

Growth Generator

• Growth Drivers
• Growth Restraints
• Need for Engineered Antibodies
• Challenges with Current Antibody Therapeutics
• How Engineered Antibodies Therapeutics Help Overcome the Challenges with Traditional Antibodies

Evolving Landscape of Therapeutic Engineered Antibodies

• Engineered Antibody Formats-Multi-specificity for Better Efficacy
• ADCs Explored for Oncology
• Antibodies Fragments/Building Blocks
• Analysis of Different Building Blocks for Different Antibody Formats
• Key Innovators
• Focus Area for Engineered Antibody Development
• Antibody Engineering-Strategies to Develop Better Antibodies
• Types of BsAb Formats
• Multispecifics Antibodies Formats/Engineering Technologies
• Multispecific Antibody Applications Across Disease Areas
• Emerging Innovations in Engineered Antibodies for Oncology
• Immune Targeting Strategies of BsAbs
• Therapeutic Utility of Fabs
• Therapeutic Utility of Bivalent Antibody Fragments F(ab')2
• Therapeutic Utility of scFvs
• Therapeutic Utility of Nanobodies/VHH
• Therapeutic Utility of Trispecific Antibodies
• Therapeutic Utility of Tetraspecific Antibodies
• Increasing Interest From Tier I Pharma Companies in Oncology

Antibody Discovery and Development

• Antibody Development Platforms-Humanized Mouse
• Antibody Development Platforms-Transgenic Animal
• Strategies to Achieve High Throughput Screening
• Innovation Around Microfluidics and Droplet-based Technologies
• Innovation Around Single Cell Analysis
• Innovation Around Functional Screening
• Use of AI/ML Across Different Aspects of Antibody Development

Stakeholder System

• Recent Private Funding for the Development of Antibody Therapeutics

Growth Opportunity Universe

• Growth Opportunity 1: Improved Optimization
• Growth Opportunity 1: Improved Optimization
• Growth Opportunity 2: Focus on Novel Antibody Formats
• Growth Opportunity 2: Focus on Novel Antibody Formats
• Growth Opportunity 3: Application Expansion
• Growth Opportunity 3: Application Expansion

Appendix

• Technology Readiness Levels (TRL): Explanation

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Take the Next Step
• Legal Disclaimer